STEPS

New Drug Reviews

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

 

Am Fam Physician. 2017 May 15;95(10):664-666.

Sofosbuvir/velpatasvir (Epclusa) is an oral medication labeled for the treatment of adults who have chronic infection with hepatitis C virus (HCV) genotypes 1 through 6. Unlike elbasvir/grazoprevir (Zepatier) and ledipasvir/sofosbuvir (Harvoni), sofosbuvir/velpatasvir can be used to treat patients with genotypes 2 and 3. It is also labeled for use in combination with ribavirin to treat patients with decompensated cirrhosis (Child-Pugh score of B or C).1,2

 Enlarge     Print

DrugStarting dosageDose formCost*

Sofosbuvir/velpatasvir (Epclusa)

One tablet per day for 12 weeks

400-mg/100-mg tablet

$75,000 for a 12-week course


*—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com (accessed March 27, 2017).

DrugStarting dosageDose formCost*

Sofosbuvir/velpatasvir (Epclusa)

One tablet per day for 12 weeks

400-mg/100-mg tablet

$75,000 for a 12-week course


*—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com (accessed March 27, 2017).

SAFETY

The main safety concern with sofosbuvir/velpatasvir is reactivation of hepatitis B virus (HBV) in coinfected patients, which is unusual but may happen with any treatment of HCV infection. All patients should be tested for HBV before starting therapy by measuring hepatitis B surface antigen (HBsAg) and anti–hepatitis B core (anti-HBc) antibody. Patients with serologic evidence of HBV infection should be monitored for clinical and laboratory signs of hepatitis flare-up or HBV reactivation during treatment and posttreatment follow-up.1,2

Sofosbuvir/velpatasvir affects or is affected by numerous medications, and a suitable drug interaction reference should be consulted before beginning treatment or when considering additional medications during treatment.1,2 Liver enzyme inducers such as rifampin, St. John’s wort, and carbamazepine (Tegretol), along with others, will decrease the therapeutic effect of sofosbuvir/velpatasvir. Proton pump inhibitors should not be taken with sofosbuvir/velpatasvir; histamine H2 receptor blockers and antacids may be used, but there are specific timing guidelines in the product labeling. Interactions with antiarrhythmics (especially amiodarone) and anticonvulsants can cause significant adverse effects. Sofosbuvir/velpatasvir has not been studied in pregnant or breastfeeding women.1

TOLERABILITY

Sofosbuvir/velpatasvir is generally well tolerated, with only 0.2% of patients discontinuing treatment in clinical trials because of adverse effects. Fatigue and headaches are the most commonly reported adverse effects.1

EFFECTIVENESS

Among patients without cirrhosis or with compensated cirrhosis, 95% to 99% will achieve sustained virologic response (defined as HCV RNA less than 15 IU per mL at 12 weeks after completion of treatment; sustained virologic response is only a biomarker for cure of HCV infection and does not imply direct effects on morbidity or mortality). In one small study comparing sofosbuvir/velpatasvir (n = 64) with placebo (n = 116) in patients with HCV genotypes 1, 2, 4, 5, and 6, 99% of the patients taking sofosbuvir/velpatasvir achieved sustained virologic response vs. none of the patients treated with placebo.1,3 In patients with HCV genotype 3, sofosbuvir/velpatasvir is more effective than sofosbuvir/ribavirin, with response rates of 95% vs. 80%, respectively.1,4

In patients with decompensated cirrhosis (Child-Pugh score of B), 94% will achieve sustained virologic response when treated with sofosbuvir/velpatasvir in combination with ribavirin.1,5 There are no studies comparing the effectiveness of sofosbuvir/velpatasvir with elbasvir/grazoprevir or ledipasvir/sofosbuvir.

PRICE

A complete 12-week course of sofosbuvir/velpatasvir will cost approximately $75,000. This price is in the same range as elbasvir/grazoprevir ($60,000 for a 12-week course; $80,000 for a 16-week course) and ledipasvir/sofosbuvir ($94,000 for a 12-week course). Adding 12 weeks of ribavirin (1,000 mg per day) will cost approximately $550 to $850 more.2

SIMPLICITY

Sofosbuvir/velpatasvir is taken orally once daily with or without food. It does not require adjustment for renal or hepatic disease.

Bottom Line

Sofosbuvir/velpatasvir is an effective treatment for patients with HCV and has minimal adverse effects. It is the preferred treatment for patients with genotype 2 or 3. As with other curative treatments, it is very expensive. Patients should be instructed to avoid using proton pump inhibitors and only take antacids and H2 blockers if timed appropriately during treatment.

Address correspondence to Randi Sokol, MD, MPH, MMedEd, at rsokol@challiance.org. Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. DailyMed. Label: Epclusa – velpatasvir and sofosbuvir tablet, film coated [prescribing information]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f. Accessed March 12, 2017....

2. Centers for Disease Control and Prevention. University of Washington, The University of Alabama at Birmingham, The International Antiviral Society–USA. Hepatitis C online. http://www.hepatitisc.uw.edu/. Accessed March 12, 2017.

3. Feld JJ, Jacobson IM, Hézode C, et al.; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607.

4. Foster GR, Afdhal N, Roberts SK, et al.; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–2617.

5. Curry MP, O’Leary JG, Bzowej N, et al.; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series coordinator for AFP is Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

 

 

Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 15, 2018

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article